ReForm Biologics Announces Collaboration Agreement with Astellas Pharma Inc.

gbaf1news

ReForm Biologics, a privately-held pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, today announced a collaboration with Astellas Pharma Inc. (TSE: 4503,Astellas) to reduce the viscosity of an Astellas clinical-stage biological pipeline program. Reforms technology platform transforms the formulation of biotherapeutics in order to enable alternative dosing, improve manufacturing efficiency and extend product life-cycles.

Under the terms of the agreement, Astellas will provide funding for the collaboration and the work will be performed at ReForm Biologics facilities in Woburn, Massachusetts.

We are excited to initiate this collaboration with Astellas, a global leader in turning innovative science into value for patients. We appreciate the efforts of Astellas Innovation Management team in getting the agreement completed, said John M. Sorvillo, Ph.D., Chief Executive Officer, ReForm Biologics. This collaboration will demonstrate how new formulation technologies can optimize dosing and support life cycle management in pharmaceutical drug development programs. We look forward to working with Astellas to support the development of this clinical-stage asset.

About ReForm Biologics

ReForm Biologics has developed a technology platform that transforms the formulation of biotherapeutics for the ultimate benefit of patients. Our patented, FDA-friendly technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for our biopharmaceutical partners. With multiple industry alliances to date, we offer formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics.

We dont make biologics we make biologics better. www.reformbiologics.com

About Astellas Pharma Inc.

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at http://www.astellas.com/en

Rob Kloppenburg
Shoreline Biotech Communications
(617) 930-5595